Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• Janus kinase (JAK) inhibitors are increasingly relevant to GI nursing practice because JAK3 and related pathways drive inflammation in inflammatory bowel disease (IBD), a condition frequently managed through endoscopic surveillance, biologic/small-molecule therapy monitoring, and patient education.
• Understanding that JAK3 signals through the common gamma chain (affecting IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) helps nurses appreciate why JAK inhibitors can broadly suppress immune activation—useful context when counseling patients on infection risk, vaccination timing, and pre-procedure screening.
• Patients on JAK inhibitor therapy (e.g., tofacitinib and related agents developed from this research lineage) require careful pre-endoscopy assessment for infection, cytopenias, and thromboembolic risk factors, which should be incorporated into pre-procedure checklists and sedation risk stratification.
• As cytokine-targeted therapies expand across autoimmune diseases seen in GI practice (IBD, and comorbid conditions like psoriatic arthritis or ankylosing spondylitis), nurses play a key role in coordinating care across rheumatology, dermatology, and gastroenterology teams.

Clinical Relevance

This foundational research into JAK3 biology underpins a therapeutic class now firmly embedded in GI practice. Small-molecule JAK inhibitors, developed from the mechanistic insights described here, are approved or under investigation for ulcerative colitis and Crohn's disease. For endoscopy and infusion unit nurses, this means an increasing number of patients presenting for colonoscopy, sigmoidoscopy, or therapeutic endoscopy will have a history of JAK inhibitor use. Nurses should be prepared to ask targeted medication-reconciliation questions, understand the rationale for periprocedural holding parameters (particularly regarding bleeding and infection risk), and recognize signs of opportunistic infection or herpes zoster reactivation, a known class effect of JAK inhibition.

Because JAK3 signaling affects multiple interleukins central to lymphocyte development and immune surveillance, patients on these therapies may have blunted inflammatory responses that mask typical signs of infection or perforation—an important consideration during post-procedure monitoring and discharge education. Nurses in IBD-focused endoscopy units should be comfortable discussing with patients why routine labs (CBC with differential, lipid panels) are monitored alongside endoscopic disease activity assessments, and how mucosal healing on colonoscopy correlates with therapeutic response to JAK-targeted agents.

From a professional development standpoint, this research also illustrates the translational pipeline from basic immunology to bedside practice—useful for nurses pursuing certification in gastroenterology nursing or seeking to deepen patient education materials. Familiarity with the "why" behind JAK inhibitor mechanisms strengthens nurses' ability to answer patient questions, support adherence, and identify early warning signs requiring provider escalation, ultimately improving continuity of care between rheumatology, dermatology, and GI teams managing overlapping autoimmune conditions.

Bottom Line

JAK inhibitors, born from discoveries about JAK3's role in cytokine signaling, are now a mainstay therapy for IBD and other autoimmune conditions seen in GI practice—making it essential for endoscopy nurses to understand their immunosuppressive mechanism, screen appropriately for infection and bleeding risk before procedures, and educate patients on monitoring requirements to ensure safe, coordinated care.